{{Infobox drug
| IUPAC_name = (''S'')-3-(((3-Ethyl-5-(2-(2-hydroxyethyl)piperidin-1-yl)pyrazolo[1,5-a]pyrimidin-7-yl)amino)methyl)pyridine 1-oxide
| image = Dinaciclib.svg
| width = 245
| alt = 
| drug_name = 
| caption =
<!-- Clinical data -->
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| licence_EU = <!-- EMA requires brand name -->
| licence_US = <!-- FDA may use generic name -->
| DailyMedID = <!-- preference to licence_US -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Investigational
| dependency_liability = 
| routes_of_administration =
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =
<!-- Identifiers -->
| CAS_number = 779353-01-4
| CAS_supplemental = 
| ATCvet = 
| ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 46926350
| PubChemSubstance = 
| IUPHAR_ligand = 7379
| DrugBank = 
| UNII = 
| KEGG = D09604
| ChEBI = 
| ChEMBL = 2103840
| PDB_ligand = 1QK
| synonyms = SCH-727965
|  ChemSpiderID = 25027387
<!-- Chemical data -->
| chemical_formula  =
| C=21 | H=28 | N=6 | Na=
| O=2
| molecular_weight  = 
| SMILES = CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO
| StdInChI = 1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1
| StdInChI_comment  = 
| StdInChIKey = PIMQWRZWLQKKBJ-SFHVURJKSA-N
| density = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| specific_rotation = 
| sec_combustion = 
}}

'''Dinaciclib''' (SCH-727965) is an experimental drug that inhibits [[cyclin-dependent kinase]]s (CDKs).<ref>{{cite journal | vauthors = Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, Wang Y, Oft M, Chen T, Kirschmeier P, Lees EM | title = Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor | journal = Molecular Cancer Therapeutics | volume = 9 | issue = 8 | pages = 2344–53 | date = Aug 2010 | pmid = 20663931 | doi = 10.1158/1535-7163.MCT-10-0324 }}</ref> It is being evaluated in clinical trials for various cancer indications.<ref name="pmid23647051">{{cite journal | vauthors = Bose P, Simmons GL, Grant S | title = Cyclin-dependent kinase inhibitor therapy for hematologic malignancies | journal = Expert Opinion on Investigational Drugs | volume = 22 | issue = 6 | pages = 723–38 | date = Jun 2013 | pmid = 23647051 | pmc = 4039040 | doi = 10.1517/13543784.2013.789859 }}</ref>

Dinaciclib is being developed by [[Merck & Co.]] It was granted [[orphan drug status]] by the FDA in 2011.<ref name ="Adis">{{cite web|title=Dinaciclib|url=http://adisinsight.springer.com/drugs/800026277|website=AdisInsight|accessdate=31 January 2017}}</ref>

== Mechanisms of action == 
*Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of [[bromodomain]]s.<ref>{{cite journal | vauthors = Martin MP, Olesen SH, Georg GI, Schönbrunn E | title = Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains | journal = ACS Chemical Biology | volume = 8 | issue = 11 | pages = 2360–5 | date = Nov 2013 | pmid = 24007471 | pmc = 3846258 | doi = 10.1021/cb4003283 }}</ref>
*Dinaciclib (SCH727665) inhibits the [[unfolded protein response]] (UPR) through a [[CDK1]] and [[CDK5]]-dependent mechanism.<ref>{{cite journal | vauthors = Nguyen TK, Grant S | title = Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism | journal = Molecular Cancer Therapeutics | volume = 13 | issue = 3 | pages = 662–74 | date = Mar 2014 | pmid = 24362465 | doi = 10.1158/1535-7163.MCT-13-0714 }}</ref>

== Anti-tumoral action ==
*In [[melanoma]]
**The anti-melanoma activity of dinaciclib is dependent on p53 signaling.<ref>{{cite journal | vauthors = Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KS, Herlyn M | title = The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling | journal = PLOS ONE | volume = 8 | issue = 3 | pages = e59588 | year = 2013 | pmid = 23527225 | pmc = 3601112 | doi = 10.1371/journal.pone.0059588 }}</ref>
*In [[chronic lymphocytic leukemia]] (CLL)
** Dinaciclib promotes [[apoptosis]] and abrogates microenvironmental [[cytokine]] protection in chronic lymphocytic leukemia cells.<ref>{{cite journal | vauthors = Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, Flynn J, Jones J, Zhang X, Bannerji R, Grever MR, Byrd JC | title = The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells | journal = Leukemia | volume = 26 | issue = 12 | pages = 2554–7 | date = Dec 2012 | pmid = 22791353 | pmc = 3645353 | doi = 10.1038/leu.2012.144 }}</ref>
*In [[pancreatic cancer]]
**Dinaciclib inhibits [[pancreatic cancer]] growth and progression in murine [[xenograft]] models.<ref>{{cite journal | vauthors = Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD | title = Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models | journal = Cancer Biology & Therapy | volume = 12 | issue = 7 | pages = 598–609 | date = Oct 2011 | pmid = 21768779 | pmc = 3218385 | doi=10.4161/cbt.12.7.16475}}</ref>
*In osteosarcoma
**Dinacliclib induces the apoptosis of osteosarcoma cells.<ref>{{cite journal | vauthors = Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J, Altiok S, Pledger WJ | title = The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells | journal = Molecular Cancer Therapeutics | volume = 10 | issue = 6 | pages = 1018–27 | date = Jun 2011 | pmid = 21490307 | doi = 10.1158/1535-7163.MCT-11-0167 }}</ref>
**Apoptosis of osteosarcoma cultures can be induced by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.<ref>{{cite journal | vauthors = Fu W, Sharma SS, Ma L, Chu B, Bui MM, Reed D, Pledger WJ | title = Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor | journal = Cell Death & Disease | volume = 4 | issue = 3 | pages = e566 | year = 2013 | pmid = 23538447 | pmc = 3613821 | doi = 10.1038/cddis.2013.101 }}</ref>

== Clinical trials ==
* Phase II
**Advanced breast cancer<ref>{{cite journal | vauthors = Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, Statkevich P, Zhu Y, Yao SL, Small K, Bannerji R, Shapiro CL | title = Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer | journal = Clinical Breast Cancer | volume = 14 | issue = 3 | pages = 169–76 | date = Jun 2014 | pmid = 24393852 | doi = 10.1016/j.clbc.2013.10.016 }}</ref>
**Non-small cell lung cancer (NSCLC)<ref>{{cite journal | vauthors = Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, Statkevich P, Yao SL, Zhu Y, Zhou H, Small K, Bannerji R, Edelman MJ | title = Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer | journal = Lung Cancer | volume = 83 | issue = 2 | pages = 219–23 | date = Feb 2014 | pmid = 24388167 | doi = 10.1016/j.lungcan.2013.11.020 }}</ref>
** Multiple myeloma<ref>https://clinicaltrials.gov/ct2/show/study/NCT01096342</ref>
** Advanced melanoma<ref>https://clinicaltrials.gov/ct2/show/NCT00937937</ref>
* Phase III
** A comparison of dinaciclib and ofatumumab for treatment of CLL<ref>https://clinicaltrials.gov/ct2/show/study/NCT01580228</ref>
== References ==
{{Reflist|33em}}

== External links ==
* {{MeshName|dinaciclib}}

[[Category:Amine oxides]]
[[Category:Experimental cancer drugs]]
[[Category:Protein kinase inhibitors]]
[[Category:Pyrazolopyrimidines]]